comparemela.com

Latest Breaking News On - Biliary tract cancer - Page 9 : comparemela.com

Senhwa s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer

TAIPEI and SAN DIEGO, Jan. 20, 2022 /PRNewswire/ Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for Silmitasertib, a highly selective inhibitor of casein kinase 2 (CK2) to treat patients.

Senhwa s Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer

Senhwa's Silmitasertib Receives US FDA Orphan Drug Designation for the Treatment of Biliary Tract Cancer - read this article along with other careers information, tips and advice on BioSpace

Rafael Pharmaceuticals to Present New Pancreatic Cancer and Biliary Tract Cancer Data featuring CPI-613® (Devimistat) at the American Society of Clinical Oncology (ASCO) 2021 Virtual Scientific Program

CRANBURY, N.J., May 26, 2021 (GLOBE NEWSWIRE) Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it will present two posters at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 4-8, 2021. These presentations will discuss the ongoing trials studying devimistat in pancreatic cancer and biliary tract cancer. “We are incredibly proud to have data to share in two hard-to-treat cancers; as challenging as the past year has been to ensure that we continue to move the needle, we have been able to make significant progress,” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. “The data continues to show us hope for the future, with our continued commitment to patients at the forefront.” Presentation Details:Title: Abstract #TPS4158: A multicenter, randomized phase 1b/2 study of gemcitabine

Biliary Tract Cancers (BTC) Market Size Anticipated to Soar During the Forecast Period 2021-30 at a CAGR of 11 69% in the 7MM, Projects DelveInsight

Erdafitinib (Janssen Research and Development). The anticipated launch of targeted therapies including potential FGFR gene fusions and somatic mutations in IDH 1/2 in iCCA, PRKACA or PRKACB gene fusions in pCCA, and ELF3 mutations in dCCA/ampullary carcinoma shall push the growth of the BTC market size in the offing.  Further, an increase in the BTC incidence, increment in healthcare spending, extensive R&D along better awareness of cancer is expected to give the BTC market size growth a much-needed momentum.  Get in touch for a holistic view of the The BTC market report also covers the market of Cholangiocarcinoma including (Intrahepatic and Extrahepatic), Gallbladder, treatment practice/algorithm, market drivers, market barriers, and unmet medical needs that help clients curate the best of the opportunities and assess the market s underlying potential, and plans strategically to tackle market risks.

NuCana plc: NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021

NuCana plc: NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021 NUC-3373 Promotes Natural Killer Cell Activation by Colorectal Cancer Cells NUC-7738 Demonstrates Anti-Cancer Activity, Prolonged Stable Disease and a Favorable Tolerability Profile in Patients with Advanced Solid Tumors NUC-7738 Generates High and Prolonged Intracellular Levels of the Active Anti-Cancer Metabolite 3 -dATP Acelarin Induces Persistent DNA Damage in Biliary Tract Cancer Cells EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 9 to 14, 2021. Data from all three of NuCana s ProTides in clinical development were presented. Summaries of the posters are described below.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.